Eight firms give Corcept Therapeutics stock a USD 138.17 target

Published on 10/17/2026 at 19:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Next earnings are scheduled for November 4, 2026. Corcept Therapeutics stock last stood at EUR 97.47 on October 16, 2026 at 10:59 p.m. CEST.

Analyst view and calendar

Eight research firms supported a USD 138.17 consensus target on October 13, 2026.
Corcept Therapeutics expects its next earnings report on November 4, 2026.
Corcept Therapeutics stock last stood at EUR 97.47 at Lang & Schwarz on October 16, 2026 at 10:59 p.m. CEST.
The company carried a price-to-earnings ratio of 262.29 on October 16, 2026.

CORT, US2183521028, Illustration mit AI erstellt.

Eight research firms supported a USD 138.17 average 12-month target for Corcept Therapeutics on October 13, 2026, according to MarketBeat. The target stands 25.43 percent above the USD 110.16 Nasdaq closing price from October 16, 2026. Corcept Therapeutics stock last stood at EUR 97.47 at Lang & Schwarz on October 16, 2026 at 10:59 p.m. CEST.

November 4 earnings date

Corcept Therapeutics is scheduled to report its next earnings on November 4, 2026, a date listed by MarketBeat. The company develops medicines that modulate cortisol effects across endocrine, oncologic, metabolic and neurologic disorders, according to its investor-relations profile at Corcept Therapeutics.

Stock position after October 16

The Nasdaq session ended at USD 110.16 on October 16, 2026, down USD 3.21 from the prior close. The session range was USD 107.79 to USD 113.64, while volume reached 849,640 shares against an average of 1,233,739 shares. The stock had gained 216.60 percent from January 1, 2026 to the October 16 close.

The wider range ran from USD 28.66 to USD 126.38 over the 52 weeks through October 16, 2026. The closing price therefore sat 12.86 percent below the high and 284.37 percent above the low. The euro quotation and the Nasdaq quotation are separate venue observations.

Valuation and analyst breadth

Corcept Therapeutics had a market capitalization of USD 11.9 billion and a price-to-earnings ratio of 262.29 on October 16, 2026. MarketBeat listed a Moderate Buy consensus based on eight research firms, with five buy ratings, one strong-buy rating, one hold rating and one sell rating. The company does not currently pay a dividend.

Comparison with peers

Corcept Therapeutics (Nasdaq, USD): P/E 262.29, market capitalization USD 11.9 billion
Vertex Pharmaceuticals (Nasdaq, USD): minus 1.77 percent, P/E 29.09, market capitalization USD 126.7 billion
Gilead Sciences (Nasdaq, USD): minus 0.75 percent, P/E minus 58.50, market capitalization USD 193.7 billion

Euro quotation remains dated

The last available euro quotation stood at EUR 97.47 at Lang & Schwarz on October 16, 2026 at 10:59 p.m. CEST. The Nasdaq close was USD 110.16 on the same date at 4:00 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Corcept Therapeutics stock.